Isaac Manke - 11 Nov 2026 Form 4 Insider Report for Addex Therapeutics Ltd. (ADXN)

Reporting relationship: Director
Issuer ticker: ADXN
Reported as of: 11 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Nov 2026, 16:00:41 UTC
Prior SEC filing: 04 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Lenaic Nathanael Teyssedou by power of attorney

Filing notes and source

Key filing fact

Isaac Manke filed Form 4 for Addex Therapeutics Ltd. (ADXN) on 13 Nov 2026.

Key facts

This page summarizes Isaac Manke's Form 4 filing for Addex Therapeutics Ltd. (ADXN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Nov 2026, 16:00.

Change

Previous filing in this sequence was filed on 04 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001622769 Primary reporting owner

Manke Isaac

Relationship: Director
Address: 405 DORADO BEACH EAST, DORADO
Signature: /s/ Lenaic Nathanael Teyssedou by power of attorney
Signature date: 13 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADXN transaction Derivative

Stock-option (Right to Buy)

Award

Transaction value
Shares: +942,854
Change %: +1886%
Price: $0.000000^*
Shares after: 992,854
Date: 11 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 942,854
Exercise price: $0.0260
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.

Footnote F2

The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.1995 per CHF 1.00 as of November 11, 2026.